Sai Life Sciences Ltd IPO Opens On December 11. Check IPO Details Issue Date Price

EspressoLogy

Sai Life Sciences Ltd IPO Opens On December 11. Check IPO Details Issue Date Price

December 10, 2024
Sai Life Sciences Ltd IPO Opens On December 11. Check IPO Details Issue Date Price

Sai Life Sciences Limited is coming out with a fresh public issue to raise Rs. 3,042.62 crores from the market.

Below are the details of the Sai Life Sciences Limited IPO:

  • Issue opens – December 11th (Wednesday)
  • Issue closes – December 13th (Friday)
  • Issue size – Rs. 3,042.62 crores
  • Price band – Rs. 522 to 549 per equity share
  • Bid lot – 27 shares and in multiples thereof.

And here are some details of the company and further details on the IPO.

Company Details:

  • Sai Life Sciences Limited are an innovator-focused, contract research, development, and manufacturing organization (“CRDMO”). They provide end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (“NCE”), to global pharmaceutical innovator companies and biotechnology firms. They possess both (a) discovery / contract research (“CRO”) and (b) chemistry, manufacturing, and control (“CMC”) / contract development and manufacturing organization (“CDMO”) capabilities. They are the fastest-growing Indian CRDMOs among listed Indian peers in terms of revenue CAGR as well as EBITDA CAGR from Financial Year 2022 to Financial Year 2024. (Source: F&S Report) Their CRDMO platform provides multiple entry points for them to acquire customers in the intermediate stages of their new drug discovery to commercialization journey.
  • They are also one of the few CRDMOs to have a differentiated delivery model of having research laboratories for discovery and development located near overseas innovation hubs at Watertown (Greater Boston, MA), United States (“US”) and Manchester, United Kingdom (“UK”), complemented by large-scale research laboratories and manufacturing facilities in cost competitive locations in India. (Source: F&S Report).
  • During the Financial Year 2024 and six months period ended September 30, 2024, they served more than 280 and 230 innovator pharmaceutical companies, respectively, including 18 of the top 25 pharmaceutical companies (in terms of revenue for the calendar year 2023), across regulated markets, including the US, the UK, Europe and Japan. (Source: F&S Report) During both the Financial Year 2024 and six months period ended September 30, 2024, they also provided CRO services to more than 60 customers, respectively, on an ongoing basis, for their integrated drug discovery programs. As of September 30, 2024, their CDMO product portfolio included more than 170 innovator pharmaceutical products, including 38 products that were supplied for manufacturing of 28 commercial drugs.
  • They provide their services through their globally accredited manufacturing and R&D facilities with quality systems that are supported by a qualified pool of scientists, engineers, and other scientific staff. As of September 30, 2024, they had 2,353 scientific staff, with majority of their scientific team holding advanced degrees, including 302 PhDs and 1,475 master’s degrees. Their manufacturing facilities have received several regulatory approvals from the United States Food and Drug Administration (“USFDA”), the Pharmaceuticals and Medical Devices Agency, Japan (“PMDA”) and the state level drug control departments which are arms of the Central Drug Standards Control Organization, India (“CDSCO”).

Issue Size : Rs. 3,042.62 Cr.

Issue break-up :

QIB – 50 % of the offer – Rs. 1521.31 Cr.
NIB – 15 % of the offer – Rs. 456.39 Cr.
RET – 35 % of the offer – Rs. 1064.92 Cr.

Listing: BSE & NSE

Registrar: Link Intime India Private Limited

UPI : All Retail & NII Bidders (bids up to Rs. 5,00,000) Applications through brokers are compulsorily in UPI Mode

Note

Application made using third party UPI or ASBA Bank A/c are liable to be rejected.

The UPI Mandate acceptance time for Retail and NII Bidders (bids up to Rs. 5,00,000) shall expire at 5:00 PM on the closing day of the IPO i.e., Friday, December 13, 2024.

Not an Espresso customer, but still want to apply for the IPORs. Become an Espresso customer in just 15 mins* by tapping here and take it from there! (* T&C apply)

Team Espresso
by Team Espresso

We care that you succeed

Bringing readers the latest happenings from the world of Trading and Investments specifically and Finance in general.